Proactive Investors - Run By Investors For Investors

Motif Bio teams up with German university to see if iclaprim can help patients with rare eye disease

Researchers at the Otto-von-Guericke University Magdeburg are to carry out a series of lab tests to evaluate iclaprim as a possible treatment for toxoplasma chorioretinitis
An orphan disease is a condition that affects fewer than 200,000 people around the world

Motif Bio PLC (LON:MTFB) is to explore the possibility of using its iclaprim next-generation antibiotic to treat people with a rare blindness-causing disease called toxoplasma chorioretinitis.

AIM-quoted Motif has tested iclparim in patients with acute bacterial skin and skin structure infections (ABSSSI), for which it is now looking to get regulatory approval.

READ: Motif bosses meet with FDA

But the company has today signed an agreement with the Otto-von-Guericke University Magdeburg in Germany which is to carry out a series of lab tests to see if iclaprim can help people affected by toxoplasma chorioretinitis.

The orphan disease that is a type of ocular toxoplasmosis – a parasitic disease that may result in severe life-threatening infections and/or blindness.

The work will be carried out by professor Ildiko Rita Dunay, a director at the university’s Institute of Inflammation and Neurodegeneration.

“We are very pleased to work with Dr Dunay, who is an expert in the area of toxoplasmosis. In vitro data indicate that iclaprim has activity against toxoplasma,” said chief medical officer David Huang.

“The data generated from Dr Dunay's lab will be important in understanding whether iclaprim can play a role in this potentially devastating, progressive and recurring necrotizing retinitis, including vision-threatening complications.”

View full MTFB profile View Profile

Motif Bio PLC Timeline

May 07 2019

Related Articles

Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use